The short version of sample stabilization fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Glutathione is a small tripeptide composed of glutamate, cysteine, and glycine, with the unusual gamma-glutamyl linkage between glutamate and cysteine. Its cysteine thiol group makes it a major non-enzymatic antioxidant in cells. The reduced form, GSH, predominates in most intracellular compartments, while the oxidized disulfide form, GSSG, is produced when GSH reduces reactive oxygen species. Intracellular concentrations often reach millimolar levels, whereas plasma concentrations are much lower, typically in the low micromolar range. This gradient reflects active synthesis, transport, and consumption rather than passive distribution.
Synthesis occurs in two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine to form gamma-glutamylcysteine, and glutathione synthetase adds glycine to complete the tripeptide. The pathway is feedback-inhibited by GSH and limited by cysteine availability, so cysteine supply often constrains production. Once formed, GSH participates in redox buffering, xenobiotic conjugation, and protein glutathionylation. Glutathione peroxidase uses GSH to reduce hydrogen peroxide and lipid peroxides, yielding GSSG, while glutathione reductase regenerates GSH using NADPH. Glutathione S-transferases conjugate electrophiles to GSH, supporting detoxification and excretion.
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C10H17N3O6S | Tripeptide of glutamate, cysteine, and glycine. |
| Molar mass | 307.32 g/mol | Calculated from the molecular formula. |
| Appearance | White to off-white powder | Typically crystalline or lyophilized solid. |
| Solubility | Soluble in water; insoluble in ethanol | Aqueous solutions are acidic and prone to oxidation. |
| Typical storage | -20 °C, desiccated, protect from light | Reduce exposure to oxygen and moisture. |
Glutathione supports detoxification by conjugating reactive electrophiles through glutathione S-transferases. The resulting conjugates are processed and exported, often after further metabolism. It also stores cysteine, transports amino acids across membranes through the gamma-glutamyl cycle, and assists in the maturation of iron-sulfur clusters and some prostaglandins. In plants, animals, and many microbes, the molecule appears in similar roles, but concentrations vary enormously between tissues. Liver, kidney, and red blood cells tend to contain high amounts, while blood plasma contains much less.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
For solid glutathione reagents, storage at low temperature and protection from moisture and light are typical precautions. Aqueous solutions can oxidize over time, and pH affects stability; alkaline conditions generally promote thiol oxidation. Some protocols prepare fresh solutions, while others use antioxidants or chelators to limit metal-catalyzed oxidation. Purity and counterion content can vary among commercial preparations, affecting concentration calculations. Certificates of analysis and validated assays help verify identity and purity.
== External links == NFE2L2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
These included French pharmacist Alexandre Rouhier's Le Peyotl: La Plante Qui Fait les Yeux Émerveillés (Peyote: The Plant That Fills the Eyes with Marvels) in 1927, the German psychiatrist Kurt Beringer's Der Meskalinrausch, seine Geschichte und Erscheinungsweise (Mescaline Intoxication, its History and Manifestation) in 1927, and German–American psychologist Heinrich Klüver's Mescal: The Divine Plant and Its Psychological Effects in 1928. Studies of the potential therapeutic effects of mescaline started in the 1950s. It was studied as part of psychedelic-assisted psychotherapy by Walter Frederking by 1953. Aldous Huxley's book The Doors of Perception, about his experience with mescaline, was published in 1954. In 1955, English politician Christopher Mayhew took part in an experiment for BBC's Panorama, in which he ingested 400 mg of mescaline under the supervision of psychiatrist Humphry Osmond. Though the recording was deemed too controversial and ultimately omitted from the show, Mayhew praised the experience, calling it "the most interesting thing I ever did" and saying that it was "profoundly thought-provoking". The mechanism of action of mescaline, activation of the serotonin 5-HT2A receptors, became fully known in the 1990s. A serotonin 5-HT2A receptor antagonist, specifically ketanserin, was first clearly shown to block the psychedelic effects of mescaline in humans by Matthias Liechti and colleagues in 2024. The history of mescaline was reviewed in the 2019 book Mescaline: A Global History of the First Psychedelic by cultural historian Mike Jay.
=== Historical taxonomy === The taxonomy of Parmotrema perlatum has a rich history marked by periods of confusion and clarification that typify the dynamic nature of botanical classification. It was originally described as Lichen perlatus by William Hudson in his 1762 work Flora Anglica. Hudson described it as a foliaceous (leafy) lichen with creeping, lobed, and smooth characteristics, having a pearly edge, a farinaceous (pruinose) texture, and a black underside, adorned with slightly scalloped, brown, stalked fruiting bodies. The taxon was later transferred to the genus Parmelia by Erik Acharius in 1803, becoming Parmelia perlata. The name was well-established in scientific literature, being cited extensively in works like Alexander Zahlbruckner's popular 1929 catalogue. In 1952, Maurice Choisy reclassified it under the current name, Parmotrema perlatum. The nomenclature of Parmotrema perlatum was revisited in the late 20th century, amid a broader effort to clarify the typification and application of early lichen names. Mason Hale, in 1961, undertook a detailed restudy of the species, selecting a lectotype from the Dillenian collections—the herbarium and associated works of Johann Jacob Dillenius housed at the University of Oxford. This solidified the application of Hudson's name and was part of a larger trend in lichenology to fix historical names to specific herbarium specimens to stabilise nomenclature. The name Parmelia perlata was widely accepted until Hale and Ahti (1986) encountered the designation Lichen chinensis, introduced by Pehr Osbeck in 1757.
=== Recreational === Being under the effects of cannabis is usually referred to as being "high". Cannabis consumption has both psychoactive and physiological effects. The "high" experience can vary widely, based (among other things) on the user's prior experience with cannabis, and the type of cannabis consumed. When smoking cannabis, a euphoriant effect can occur within minutes of smoking. Aside from a subjective change in perception and mood, the most common short-term physical and neurological effects include increased heart rate, increased appetite, impairment of short-term and working memory, and impairment of psychomotor coordination. Additional desired effects from consuming cannabis include relaxation, a general alteration of conscious perception, increased awareness of sensation, increased libido and distortions in the perception of time and space. In some cases, cannabis can lead to dissociative states such as depersonalization and derealization. Cannabis at high doses can produce strong hallucinogenic effects in some people.
Sources: en.wikipedia.org
== Science and technology == Octadecylsilyl, also known as C18, a surface coating used in reversed-phase chromatography Oxide dispersion strengthened alloys Ozone-depleting substance, chemicals which contribute to ozone depletion Osmotic demyelination syndrome, a neurological condition involving severe damage to the myelin sheath of nerve cells Obstructed defecation syndrome, a major cause of functional constipation
== History == After the description of fibrinogen and fibrin, Alexander Schmidt hypothesised the existence of an enzyme that converts fibrinogen into fibrin in 1872. Prothrombin was discovered by Pekelharing in 1894.
== Background == Casey is of Mexican descent. A former Division I soccer player at the University of Texas at El Paso, Casey began training MMA in 2009 after her soccer career was cut short due to an injury. She began her amateur career in 2012, and her professional career a year later.
The Australasian Proteomics Society (APS) is a learned society formed in 2004 from the Lorne Proteomics Symposia (LPS) meetings. The APS was expanded to include the Australian Electrophoresis and Proteomics Society (a society formed in 1994 in Sydney, Australia and originally called the Australian Electrophoresis Society, part of the International Council of Electrophoresis Societies). The Lorne Proteomics Symposia meetings can trace their roots to the original Specialist Protein Analysis Workshop (SPAW) founded by Robert L. Moritz and Richard J. Simpson. These meetings began in 1994 as an offshoot of the Lorne Protein Meeting. (established in 1974) to address the needs of protein purification and analysis technologies rapidly under development in the 1980s. The founding president and vice president were Simpson and Moritz. The current president is Stuart Cordwell. In 2004, an Australasia-wide committee was formed to fully disseminate the activities of the APS and provide a regional society to include New Zealand and other interested Asian countries to be a focal hub in the Pacific for the Human Proteome Organization. The aims of the APS are to promote and facilitate proteomics research and related topics. The APS acts a liaison body for communication with state and federal government as well as a central point for the coordination of proteome-related programmes and resources. The APS is a member of the Asia Oceania Human Proteome Organization.
== Industry evolution == Liquid chromatography as we know it today really got its start in 1969, when the first modern HPLC was designed and marketed as a nucleic acid analyzer. Columns throughout the 1970s were unreliable, pump flow rates were inconsistent, and many biologically active compounds escaped detection by UV and fluorescence detectors. Focus on purification methods in the '70s morphed into faster analyses in the 1980s, when computerized controls were integrated into HPLC equipment. Higher degrees of computerization then led to emphasis on more precise, faster, automated equipment in the 1990s. Atypical of many technologies of the '60s and '70s, the emphasis in improvements was not on “bigger and better,” but on “smaller and better”. At the same time the HPLC user-interface was improving, it was critical to be able to isolate hundreds of peptides or biomarkers from ever decreasing sample sizes. Laboratory analytical instrumentation has only been recognized as a separate and distinct industry by NAICS and SIC since 1987. This market segmentation includes not only gas and liquid chromatography, but also mass spectrometry and spectrophotometric instruments. Since first recognized as a separate market, sales of analytical laboratory equipment increased from about $3.5 billion in 1987 to more than $26 billion in 2004.
Sources: en.wikipedia.org
GSH is the reduced, thiol-containing form of glutathione, while GSSG is the oxidized disulfide dimer formed when two GSH molecules react. Cells maintain a high GSH-to-GSSG ratio under normal conditions. A shift toward GSSG is often interpreted as oxidative stress, though sample handling can affect the measured ratio.
No. It is a tripeptide made from three amino acids: glutamate, cysteine, and glycine. The gamma-glutamyl bond is unusual and distinguishes it from typical peptide linkages.
Most ingested glutathione is broken down in the gastrointestinal tract into its constituent amino acids. Some formulations may protect it from digestion, but intact absorption and delivery to specific tissues remain uncertain. Research continues on precursors and delivery methods.
Common approaches include enzymatic recycling assays, HPLC, and LC-MS/MS. Acid extraction and rapid processing limit oxidation before analysis.